COVID-19 Vaccine (Vero Cell), Inactivated - CoronaVac®

COVID-19 Vaccine CoronaVac®Hub


Conditioned market authorization in China on February 5, 2021


  • The results of pre-clinical and clinical research trials were published in Science and Lancet Infect Diseases.


  • The Phase Ⅲ Clinical Trial and real-world studies showed that vaccination with CoronaVac® has a significant impact on reducing the incidence, hospitalization and death rate caused by COVID-19 infection.


  • Over 400 studies conducted worldwide showed its safety and efficacy among people aged 6 months old and above, including some special populations


  • Real-world studies showed it had effective protection against VOCs


  • The annual production capacity is over 2 billion doses


  • CoronaVac® vaccine has been approved for administration to adults in 62 countries, regions, and international organizations, and for children and adolescents in 14 countries and regions. CoronaVac® is the only inactivated COVID-19 vaccine currently approved for use in children as young as 6 months old


  • Nearly 290 million doses of vaccines have been delivered worldwide and recognized internationally and which can facilitate multi-national trade



Related news
year:
--ALL--
  • --ALL--
Load More
© SINOVAC